https://www.selleckchem.com/pr....oducts/AZD1152-HQPA.
BACKGROUND Kidney transplantation in HIV-infected patients is characterized by a concerning high rate of allograft rejections. The etiological mechanisms leading to this increased immunoreactivity are still unknown. Maraviroc is a new antiretroviral agent that has been associated with immunomodulatory proprieties; therefore, its use may be a promising strategy to minimize the rate of rejections in HIV-infected kidney transplant (KT) recipients. METHODS We conducted a retrospective study in our cohort of HIV- KT recipients with the
إعجاب
علق
شارك
